143 related articles for article (PubMed ID: 15743572)
1. [Hepatitis C and HIV in Spanish prisons].
Soriano V; González-Lahoz J
Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):51-2. PubMed ID: 15743572
[No Abstract] [Full Text] [Related]
2. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
Saiz de la Hoya-Zamácola P; Marco-Mouriño A; Clemente-Ricote G; Portilla-Sogorb J; Boix-Martínez V; Núñez-Martínez O; Reus-Bañuls S; Teixidó i Pérez N
Enferm Infecc Microbiol Clin; 2006 Nov; 24(9):568-75. PubMed ID: 17125677
[TBL] [Abstract][Full Text] [Related]
3. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
[TBL] [Abstract][Full Text] [Related]
4. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
Martínez-Bauer E; Forns X
Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
[No Abstract] [Full Text] [Related]
5. [Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients].
Pérez García ML; Alvarez Delgado A; Fuertes Martín A
An Med Interna; 2005 Jun; 22(6):288-92. PubMed ID: 16011410
[TBL] [Abstract][Full Text] [Related]
6. Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients.
De Luca A; Di Giambenedetto S; Cingolani A; Ammassari A; Marasca G; Tumbarello M; Fantoni M; Tamburrini E; Cauda R
AIDS; 2004 Jul; 18(11):1602-4. PubMed ID: 15238782
[TBL] [Abstract][Full Text] [Related]
7. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058
[No Abstract] [Full Text] [Related]
8. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
[TBL] [Abstract][Full Text] [Related]
9. [Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison].
Sáiz de la Hoya P; Bedia M; Murcia J; Cebriá J; Sánchez-Payá J; Portilla J
Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):53-7. PubMed ID: 15743573
[TBL] [Abstract][Full Text] [Related]
10. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P
AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063
[No Abstract] [Full Text] [Related]
11. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
Wedemeyer H; Cornberg M; Manns MP
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
[No Abstract] [Full Text] [Related]
12. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Taylor LE; Rich JD; Tashima KT
N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
[No Abstract] [Full Text] [Related]
13. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Gholam PM
N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
[No Abstract] [Full Text] [Related]
14. Comment on a systematic review of randomized trials of peginterferon alpha-2a versus peginterferon alpha-2b in chronic hepatitis C.
Singal AK; Jampana SC; Anand BS
Hepatology; 2011 Jun; 53(6):2151. PubMed ID: 21538429
[No Abstract] [Full Text] [Related]
15. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
[No Abstract] [Full Text] [Related]
16. [Primer treatment of acute and chronic hepatitis C].
Daruich J; Fainboim H; Frider B
Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S52-6; discussion S74-82. PubMed ID: 16862862
[No Abstract] [Full Text] [Related]
17. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis C virus infection.
Flamm SL
JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of pegylated interferon and ribavirin in adolescents with human immunodeficiency virus and hepatitis C virus acquired perinatally.
Rosso R; Di Biagio A; Mikulska M; Nicco E; Bernardini C; Viscoli C
J Med Virol; 2010 Jul; 82(7):1110-4. PubMed ID: 20513072
[TBL] [Abstract][Full Text] [Related]
20. [Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study].
de Juan J; Faraco I; Saiz de la Hoya P; Marco A; Yllobre C; Da Silva A; del Pozo E; Veiras FM;
Rev Esp Sanid Penit; 2011; 13(2):44-51. PubMed ID: 21750854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
